After the Slovenian Health Insurance Fund expressed interest, Lenis started supplying and obtained reimbursement for this unlicensed medicine more than 10 years ago.
The market potential then was estimated by a leading specialist to be 10.000 packs per year. Since then, this product became the leading UTI medicine in Slovenia with over 60.000 packs sold in 2022. Over the years, Lenis managed to mitigate supply chain issues with a variety of regulatory and commercial tools.
As a local regulatory agent, Lenis helped the principal obtain marketing authorization through a shortened procedure (Cyprus clause). This is still the only Rx product in the country with an MA based on the Cyprus clause.